Callan JMB is a vertically integrated logistics and fulfillment company which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. We provide a system that utilizes advanced predictive technology to revolutionize the supply chain by guaranteeing the safety, effectiveness, and potency of every product handled to ensure product integrity, and to provide immediate response in time-sensitive industries while ensuring environmental responsibility. We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, and economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). As part of our services, we provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes. Our Ship2Q® ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturer specifications equal to new “off-the-shelf” shipper systems. Our systematic Ship2Q® process meets all good current manufacturing practices (“cGMP”) and good current distribution practices (“cGDP”) compliance standards and generates shipper specific track and trace documentation key to any deployment and reuse. Ship2Q® applies a system of control over the recovery and reuse phase of the logistics loop. We are able to recover and reuse the Greenbox shipper, amortizing its total cost across numerous shipments making it cost-neutral in the first few cycles. Additionally, our sophisticated cloud-based logistics operating platform, which is branded as our “Sentry” system, integrates GPS and precise temperature diagnostics throughout a package’s journey, maintaining the efficacy, safety, and quality of temperature-sensitive goods throughout transit—with zero bench time required. The Sentry system supports the management of the entire shipment and logistics process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment. The Sentry platform records and retains a fully documented “chain-of-custody” and, at the client’s option, “chain-of-condition” for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our clients to meet exacting requirements necessary for scientific work and for proof of regulatory compliance during the logistics phase. With extensive experience in quality assurance and quality control, we deliver reliability by anticipating, responding, and overcoming the most complex situations with precision and compassion, providing peace of mind and a comprehensive solution for our customers. This empowers the healthcare and emergency response industries with solutions to ensure temperature-sensitive goods remain within specified parameters throughout transit through tracking mechanisms and predictive technology to ensure its integrity for patients, providers, and their communities. We were originally formed as Coldchain Technology Services, LLC, a Texas limited liability company. We reorganized as a holding company to Callan JMB Inc., a Nevada corporation, on February 14 2024. We are headquartered at 244 Flightline Dr., Spring Branch, TX 78070.
AI Generated Analysis | Feedback
1. An investment equivalent of McKinsey & Company, advising large institutions on their investment strategy and asset allocation.
2. A highly specialized financial consulting firm, akin to Deloitte or Accenture, but exclusively dedicated to helping large institutions (like pension funds and endowments) optimize their investment portfolios.
3. Like a Gartner for institutional investment managers, providing independent research and advice to help select the best fund managers and strategies.
AI Generated Analysis | Feedback
- Investment Consulting: Provides strategic advice to institutional investors on asset allocation, manager selection, performance evaluation, and risk management for their investment portfolios.
- Manager Research: Conducts in-depth, proprietary research on investment managers, strategies, and capital markets to inform client recommendations.
- OCIO Solutions (Outsourced Chief Investment Officer): Offers comprehensive, discretionary investment management and oversight services for institutional clients.
AI Generated Analysis | Feedback
Please note that Callan Jmb (symbol: CJMB) is not a public company, and the provided symbol is incorrect. The company you are likely referring to is Callan LLC, which is a privately held investment consulting firm.
Callan LLC primarily sells its services to other organizations, specifically institutional investors, rather than individuals.
While specific customer names are typically confidential due to the nature of their consulting business, Callan LLC serves a broad range of institutional clients. Their major customer categories (types of organizations) include:
- Pension Funds: This extensive category encompasses corporate pension plans, public sector retirement systems (e.g., state, county, municipal funds), and Taft-Hartley (multi-employer) pension plans.
- Endowments: These are investment funds established by non-profit organizations to provide a perpetual source of income. Clients include university endowments, hospital endowments, and other charitable institution endowments.
- Foundations: Non-profit organizations (e.g., private foundations, community foundations) that often manage significant investment portfolios to fund their philanthropic activities.
- Defined Contribution Plans: Callan advises on a variety of defined contribution schemes, such as 401(k), 403(b), and 457 plans, helping organizations with investment menu design, manager selection, and overall oversight.
AI Generated Analysis | Feedback
Wayne Williams Chief Executive Officer, Chairman & Founder, President
Wayne Williams founded Callan JMB in 2006. He also serves as the Executive Director of Warehouse Asset Management (WAM). Previously, Mr. Williams was the Director of Logistics for Logistics Health Inc. (LHI), where he was responsible for the management and oversight of LHI's Supply Support Technology Group, served on the General Logistics Council for all logistical operations, and was the primary inventor for LHI's Environmental Witness System. He is recognized as a leading expert in Cold Chain Management, with processes he developed being utilized within LHI's Supply Support Technology Group, the Strategic National Stockpile Program, and the Department of Defense Distribution Operations Center at the US Army Medical Materiel Agency. He also served as the Associate Director of Logistics for the Strategic National Stockpile (SNS) from its inception through its post-9/11 expansion.
Shannon Badger Interim Chief Financial Officer
Shannon Badger was appointed as the interim Chief Financial Officer on May 13, 2025. She brings extensive experience from her previous roles at Badger CPA and Tesoro Corporation.
Eric L. Kash Executive Vice President & Director
Eric L. Kash has worked across various aspects of the United States securities markets, encompassing Retail and Institutional Equity Sales to Investment Banking. He has held positions as a public company CEO and CFO, possessing both an MBA and CPA. In the past, he has focused on assisting private companies in their efforts to go public and has expertise in new business development. Prior to joining Callan JMB, since 2015, Mr. Kash served as the President of Alpha Kash, LLC, a business consultancy service. Between January 2008 and March 2013, he was the CEO/CFO of Coupon Express Inc., a publicly traded company, and spent over a decade as an investment banker in the microcap sector.
Scott Bullard Chief Operating Officer
Scott Bullard works directly with Warehouse Asset Management (WAM).
Wiliam McBride Chief Information Officer
Wiliam McBride holds a Bachelor of Science in Biology from Frostburg State and a Master of Science in Quality Assurance (MSQA) from California State University. He was responsible for implementing a GMP quality assurance system at one of the nation's largest biological specimen repositories, where he managed over 12 million samples, more than 600 pieces of refrigeration equipment, over 800 recording instruments, and 6 separate facilities. He also served as the Manager of Compliance and Program Evaluation at Logistics Health, Inc.
AI Generated Analysis | Feedback
The public company Callan JMB (symbol: CJMB) faces several key risks, primarily centered on its financial performance and market volatility.
- Significant Financial Losses and Weak Financial Health: Callan JMB has reported substantial financial losses. For the first quarter of 2025, the company recorded a net loss of $1.2 million against revenues of $1.45 million. Over the last 12 months, the company experienced total losses of $6.67 million on $5.91 million in revenue, resulting in a loss per share of -$1.68. Its operating and profit margins are deeply negative, at -98.02% and -112.75% respectively, despite a gross margin of 36.68%. Furthermore, the company has less than one year of cash runway, and its Altman Z-Score of 1.01 indicates an increased risk of bankruptcy, as a score under 3 suggests elevated risk. The company's financial health is generally rated as weak.
- Small Market Capitalization and High Stock Volatility: Callan JMB possesses a relatively small market capitalization of $8 million. The company's share price has demonstrated significant volatility over the past three months compared to the broader U.S. market. The stock is considered "very high risk" due to its substantial daily price movements, which have fluctuated by as much as 16.25% in a single day, and its high weekly volatility of 14%. The stock price has seen a considerable decline, falling by nearly 57% over the past year.
AI Generated Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Callan Jmb (CJMB) over the next 2-3 years:
- Expansion into new temperature-controlled logistics markets: Callan JMB is actively pursuing growth opportunities in rapidly expanding sectors, specifically mentioning GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services. The company aims to leverage its core competitive strengths to scale its business model into these emerging markets.
- International expansion, particularly in India: The company has launched a new subsidiary in India and is in the process of constructing a warehouse. This facility is intended for full-spectrum temperature control, targeting pharmaceutical distribution and clinical trial logistics for international partners.
- National geographic expansion of emergency preparedness and response operations: Despite a recent decline in demand for its core emergency preparedness services from some state and local governments, Callan JMB plans to accelerate its geographic expansion into "untapped metropolitan areas and states" within the U.S.
- Strategic partnerships for new service offerings: Callan JMB has formed a strategic alliance with Revival Health Inc. This partnership is expected to create new opportunities in the health, wellness, and longevity product sectors, broadening the company's target customer base.
AI Generated Analysis | Feedback
Share Issuance
- In February 2025, Callan JMB completed its initial public offering (IPO), raising approximately $5.12 million in gross proceeds through the sale of 1,280,000 shares at $4.00 per share.
- The company granted underwriters a 45-day option to purchase up to an additional 192,000 shares at the public offering price.
- Net proceeds from the IPO are intended primarily for sales support, marketing, customer expansion, and general corporate purposes, including working capital.
Outbound Investments
- Callan JMB launched a subsidiary in India in 2025, with plans to establish a temperature-controlled warehouse for the storage and distribution of pharmaceuticals.
Capital Expenditures
- Capital expenditures for the last 12 months amounted to approximately -$447,799.
- The company's capital expenditures growth is forecasted to be 592.2%.
- Primary focuses of capital expenditures include establishing temperature-controlled warehouses in India and upgrading the Sentry Monitoring System technology for mobile temperature monitoring.
